| Species |
Mouse |
| Protein Construction |
Kallikrein 5/KLK5 (Gly30-Asn293)_x000D_
Accession # Q9D140 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its ability to cleave the fluorogenic peptide substrate BocVPRAMC. The specific activity is > 1,350 pmol/min/μg. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
29.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM NaAc, 150mM NaCl (pH 5.0). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 20mM NaAc, 150mM NaCl (pH 5.0). |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches. |
| Synonyms |
Kallikrein c; Klnc; KLK5; KLKL2; KLK-L2; SCTE |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
